MedTrace Logo

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

NCT03061656 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-09-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCT including high-dose 131I-metaiodobenzylguanidine (MIBG) treatment. In the present study, a single arm trial of tandem HDCT/ASCT will be carried out.

Conditions

  • High Risk Neuroblastoma

Interventions

DRUG

Cyclophosphamide

1st HDCT

DRUG

Carboplatin

1st HDCT

DRUG

Etoposide

1st HDCT

RADIATION

131I-MIBG

2nd HDCT

DRUG

Thiotepa

2nd HDCT

DRUG

Melphalan

2nd HDCT

Sponsors & Collaborators

  • Ministry of Health, Republic of Korea

    collaborator OTHER_GOV

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Ki Woong Sung · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-01
Primary Completion
2013-12-31
Completion
2018-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03061656 on ClinicalTrials.gov